Jonathan Loree
@jonathanloree
Followers
806
Following
2K
Media
106
Statuses
913
GI Medical Oncologist at BC Cancer, Associate Professor at The University of British Columbia, Senior Investigator at the Canadian Cancer Trials Group (CCTG)
Vancouver, British Columbia
Joined March 2014
RT @SuyogCancer: What if this was a drug ?🙂 . 🆕 NEJM | June 2025.🎯 CHALLENGE Trial: Structured exercise after adjuvant chemo in colon can….
0
129
0
RT @JAMAOnc: Both hand cooling and compression were effective in preventing sensory chemotherapy-induced peripheral neuropathy during taxan….
0
11
0
RT @JAMAOnc: Cell-free DNA (cfDNA) testing could improve colorectal cancer detection and reduce mortality in Canada, but it requires higher….
0
6
0
RT @davidasinclair: 12 lessons students learn in the Sinclair Lab:. Lesson 1. Write the way you speak
0
216
0
RT @TheLancetOncol: New research: Neoadjuvant chemoradiotherapy followed by active surveillance versus standard surgery for #oesophagealcan….
0
32
0
RT @matteolambe: Just published in @JCO_ASCO the updated @ASCO guidelines on fertility preservation in people with #cancer: a must read for….
0
200
0
RT @GillSharlene: #GI25 ❤️ @ASCO .So proud to see our past and present #oncology trainees thriving & making their mark! .@jaypsv @jonathanl….
0
3
0
RT @CathyEngMD: @NCICTEP_ClinRes @SWOG @CDNCancerTrials #Coloncancer Task Force Chairs @smitha42 @jonathanloree hard at work at Oral Presen….
0
3
0
RT @ArndtVogel: 🔥off the press:.The use of immunotherapy pre-liver transplant.@JHepatology .👉Hepatology Snapshot.👉O….
0
66
0
RT @CRC_AACR: Recently published:.#ClonalHematopoiesis of Indeterminate Potential (CHIP) & Its Association with Treatment Outcomes & Advers….
0
3
0
RT @GillSharlene: Nice to see CM8HW in press! @NEJM .📌 n=303 centrally confirmed dMMR mCRC 1L.➡️ 2y PFS 72% nivo-ipi vs 14% chemo 🌟 .Per ea….
0
23
0
RT @HalletJulie: ‼️What guidelines are needed in #NETs care?.@nanets1 needs your input!🫵🏻. Stop by guidelines board at #NANETS24 to leave y….
0
4
0
Joint #CommNETs & @NANETS1 guidance document on treatment informing features in NETs. Supplements loaded with comprehensive reviews of data for each biomarker (highlights where we need to generate data!) and patient education document co-developed with @CNETSCanada @NECancerAus.
This study provides a guidance document to educate clinicians and patients on biomarkers informing prognosis and treatment in unresectable or metastatic gastroenteropancreatic neuroendocrine neoplasms.
0
3
12
RT @ArndtVogel: 🔥of the press.Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial.@NatureM….
0
58
0
RT @ArndtVogel: Vitamin D with CTx + bevacizumab in previously untreated mCRC.#ESMO24.🔎SOLARIS (Alliance A021703).👉ORR 51 vs 44%.👉mPFS 11.8….
0
17
0
RT @drcarl_vancouvr: NEO outcomes min 3 yr f/up presented at #ESMO2024 !. Neoadj FOLFOX/CAPOX + TES great for organ preserv’n in early rect….
0
14
0
RT @GillSharlene: #ESMO24 @myESMO .CABINET - ph3 cabozantinib vs placebo in pre-treated advanced #Neuroendocrine NETs @ALLIANCE_org @NEJM J….
0
32
0
RT @sepideh_gholami: It was a team effort! @ajscott40 @HKennecke @VanMorrisMD @manjuggm @jonathanloree @JoshSmithMDPhD @jordanberlin5 @MayC….
0
4
0
RT @HKennecke: We have data now to personalize #rectalcancer treatment. Based on tumor factors and patient preferences. Gone are the da….
0
8
0